Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD08RH)

• Drug Name: Acetate Ion Drug Info
• Synonyms: acetate; Acetate Ion; Acetic acid, ion(1-); Acetate ions; 71-50-1; monoacetate; MeCO2 anion; UNII-569DQM74SC; ethanoate; Acetat; 569DQM74SC; Shotgun; Ethanoat; CHEMBL1354; racemic acetate; Azetat; acetyl hydroxide; Acetic acid ion; Acetic cid glacial; TCLP extraction fluid 2; AC1Q1J9D; AC1Q1J2O; CH3-COO(-); AC1L18N9; DTXSID1037694; CTK5D4394; CHEBI:30089; MolPort-006-169-563; QTBSBXVTEAMEQO-UHFFFAOYSA-M; STL282721; CMC_13391; BDBM50159793; AKOS022101130; AN-25008; AN-23801; LS-189936; 1395-EP2380874A2; 1395-EP2380661A2; 1395-EP2316837A1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 175
  ChEBI ID: CHEBI:30089
  CAS Number: CAS 71-50-1
  TTD Drug ID: DMD08RH

Molecule-Related Drug Atlas

Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[2]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[3]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[4]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[5]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[6]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[7]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[1]
1,4-Naphthoquinone	DMTCMH7	Discovery agent	N.A.	Investigative	[6]
Dihydroorotate	DM76BGZ	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Matrix metalloproteinase-12 (MMP-12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Neovastat	DMXTYWJ	Non-small-cell lung cancer	2C25.Y	Phase 1	[9]
FP-025	DMH1NXO	Asthma	CA23	Phase 1	[10]
PMID29130358-Compound-Figure17(12)	DMML4PA	N. A.	N. A.	Patented	[11]
PMID29130358-Compound-Figure17(10)	DMVA15O	N. A.	N. A.	Patented	[11]
PMID29130358-Compound-Figure17(11)	DMSZA9L	N. A.	N. A.	Patented	[11]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[12]
AZD1236	DML3RSF	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[13]
V85546	DMLFMSY	Inflammation	1A00-CA43.1	Discontinued in Phase 1	[14]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	DMCNV5J	Discovery agent	N.A.	Investigative	[15]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	DM37C25	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting Leukotriene A-4 hydrolase (LTA4H)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bestatin	DM8L9D4	Acute myeloid leukaemia	2A60	Approved	[16]
Acebilustat	DM19UTO	Chronic blistering skin disorder	ME63.3	Phase 1	[17]
DG051	DM3I0GS	Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[18]
JNJ-10392980	DMZH0K8	Discovery agent	N.A.	Investigative	[19]
4-(2-amino-1,3-thiazol-4-yl)phenol	DMH5CAQ	Discovery agent	N.A.	Investigative	[20]
2-(4-phenoxyphenoxy)ethanamine	DM7TBUJ	Discovery agent	N.A.	Investigative	[21]
3-(Benzyloxy)Pyridin-2-Amine	DM35VEI	Discovery agent	N.A.	Investigative	[1]
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine	DMD2QVO	Discovery agent	N.A.	Investigative	[22]
2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole	DMMYJ3R	Discovery agent	N.A.	Investigative	[19]
N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide	DMTO8KS	Discovery agent	N.A.	Investigative	[23]

Drug(s) Targeting Nitric-oxide synthase endothelial (NOS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tilarginine acetate	DMZBGI8	Myocardial infarction	BA41-BA43	Phase 3	[24]
L-NAME	DM01SR6	Hypertension	BA00-BA04	Phase 2	[25]
ACCLAIM	DM0FGDO	Angina pectoris	BA40	Phase 2	[26]
VAS-203	DMKU93J	Brain injury	NA07.Z	Phase 2	[27]
MTR105	DMT0K4F	Hypotension	BA20-BA21	Phase 2	[28]
Autologous cell based gene therapy	DMQA1VT	Pulmonary hypertension	BB01	Phase 1	[29]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[30]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[20]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Hydroxyphenylpyruvate dioxygenase (HPD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitisinone	DMVS9WQ	Hereditary tyrosinemia type 1	5C50.11	Approved	[31]
BMS-433771	DME20VP	Respiratory syncytial virus infection	1C80	Terminated	[32]
2-(2-Nitro-benzoyl)-cyclohexane-1,3-dione	DMUJQX1	Discovery agent	N.A.	Investigative	[33]
2-(2-Iodo-benzoyl)-cyclohexane-1,3-dione	DMSVHU9	Discovery agent	N.A.	Investigative	[33]
2-(2-Bromo-benzoyl)-cyclohexane-1,3-dione	DM3VH7F	Discovery agent	N.A.	Investigative	[33]
Diketonitrile	DMPKQER	Discovery agent	N.A.	Investigative	[34]
2-(2-Methoxy-benzoyl)-cyclohexane-1,3-dione	DMESMBO	Discovery agent	N.A.	Investigative	[33]
3-Hydroxy-4-phenyl-5H-furan-2-one	DM5QZDL	Discovery agent	N.A.	Investigative	[35]
(4-Hydroxy-phenoxy)-acetic acid	DMRCM5O	Discovery agent	N.A.	Investigative	[35]
2-(2-Chloro-benzoyl)-cyclohexane-1,3-dione	DMG6ABE	Discovery agent	N.A.	Investigative	[33]

Drug(s) Targeting Bacterial Glucosamine-6-phosphate synthase (Bact glmS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucose-6-phosphate	DMKY1L4	N. A.	N. A.	Phase 1	[1]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
2-(N-Morpholino)-Ethanesulfonic Acid	DMZVHSB	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Glucose-6-Phosphate	DMR0EVN	Discovery agent	N.A.	Investigative	[1]
Glutamine Hydroxamate	DMT7K0U	Discovery agent	N.A.	Investigative	[1]
2-Deoxy-2-Amino Glucitol-6-Phosphate	DMBMK4T	Discovery agent	N.A.	Investigative	[1]
Glucosamine 6-Phosphate	DMY590Q	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Mycobacterium Biosynthetic alanine racemase (MycB alr)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[1]
Pyridoxamine-5'-Phosphate	DMQ6POC	Discovery agent	N.A.	Investigative	[1]
Lysine Nz-Carboxylic Acid	DMW1YK3	Discovery agent	N.A.	Investigative	[1]
Propionate	DM0O8N6	Discovery agent	N.A.	Investigative	[36]
Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate	DM7AW0X	Discovery agent	N.A.	Investigative	[1]
N-(5'-Phosphopyridoxyl)-D-Alanine	DM3FCAI	Discovery agent	N.A.	Investigative	[1]
Pyridoxyl-Alanine-5-Phosphate	DMUVCWY	Discovery agent	N.A.	Investigative	[1]
Propanoic Acid	DM9TN2W	Discovery agent	N.A.	Investigative	[1]
3-fluorovinylglycine	DMECBLA	Discovery agent	N.A.	Investigative	[37]

Drug(s) Targeting Nitric-oxide synthase brain (NOS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[38]
NXN-462	DMWVBS2	Headache	8A80-8A84	Phase 2	[39]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[30]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[1]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[20]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[1]
2'-Monophosphoadenosine 5'-Diphosphoribose	DME9S8M	Discovery agent	N.A.	Investigative	[1]
6-isobutyl-4-methylpyridin-2-amine	DM2XB68	Discovery agent	N.A.	Investigative	[40]
7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	DMUCJA6	Discovery agent	N.A.	Investigative	[41]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[42]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[43]
Dorzolamide	DMA17D0	Open-angle glaucoma	9C61	Approved	[44]
Chlorothiazide	DMLHESP	Congestive heart failure	BD10	Approved	[45]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[20]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[20]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[46]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[47]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[48]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[49]

Drug(s) Targeting Pancreatic elastase 1 (CELA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha 1-PI	DMXC1K9	Alpha-1 antitrypsin deficiency	5C5A	Approved	[50]
Erdosteine	DM6QFSV	Bronchitis	CA20	Approved	[51]
Sivelestat	DM6BZCV	Crohn disease	DD70	Phase 3	[52]
Mdl 101,146	DMRSOBG	Inflammation	1A00-CA43.1	Terminated	[1]
WIN-63759	DMRV48P	Emphysema	CA21	Terminated	[53]
SSR-69071	DMWL4MI	Chronic obstructive pulmonary disease	CA22	Terminated	[54]
SYN-1134	DMG2SQM	Cystic fibrosis	CA25	Terminated	[55]
PBI-1101	DMWD1RC	Inflammation	1A00-CA43.1	Terminated	[56]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[57]
Dimethylformamide	DML6O4N	Discovery agent	N.A.	Investigative	[58]

Drug(s) Targeting Superoxide dismutase Cu-Zn (SOD Cu-Zn)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Coprexa	DMA0WEK	Neurological disorder	6B60	Phase 3	[59]
BIIB067	DM0AEDT	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[38]
Tempol	DMUQH78	Spinal cord injury	ND51.2	Phase 2	[60]
Superoxide dismutase	DMSWPA6	Myocardial infarction	BA41-BA43	Phase 2	[61]
Midismase	DMGCRKY	Cerebral infarction	8B11.5Z	Phase 2	[62]
Methoxyestradiol	DMHSL87	N. A.	N. A.	Phase 2	[63]
ATN-224	DMQJ5DV	Solid tumour/cancer	2A00-2F9Z	Phase 2	[59]
PC-SOD	DMUHDX3	Interstitial lung disease	CB0Z	Phase 2	[62]
APN-201	DMV7Q6X	Dermatitis	EA80-EA89	Phase 1/2	[64]
EUK-189	DMY9ZAS	Skin burns	ME65.0	Phase 1	[65]

Drug(s) Targeting Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2'-deoxyuridylic acid	DMPV1LU	Discovery agent	N.A.	Investigative	[1]
Deoxyuridine-5'-Triphosphate	DMCG5V2	Discovery agent	N.A.	Investigative	[1]
1-[(Z)-4-trityloxy-2-butenyl]uracil	DMIHBFO	Discovery agent	N.A.	Investigative	[66]
2'-deoxyuridine 5'-alpha,beta-imido-diphosphate	DMXV27U	Discovery agent	N.A.	Investigative	[16]
1-[2-(trityloxy)ethoxymethyl]uracil	DM98F0U	Discovery agent	N.A.	Investigative	[66]
1-[4-hydroxy-3-(tritylaminomethyl)butyl]uracil	DMHXAMR	Discovery agent	N.A.	Investigative	[66]
Deoxyuridine-5'-Diphosphate	DMIFMDC	Discovery agent	N.A.	Investigative	[16]
1-(3-tritylaminopropyl)uracil	DMZPJM4	Discovery agent	N.A.	Investigative	[66]
2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate	DMOHABR	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Phospholipase A2 (PLA2G1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic acid	DM7OKQV	Peroxisomal disorder	5C57	Approved	[1]
Miltefosine	DMND304	Leishmaniasis	1F54	Approved	[67]
Clocortolone	DM9ZMQH	Rosacea	ED90.0	Approved	[68]
Clobetasol	DMUXP52	Rosacea	ED90.0	Approved	[69]
Diflorasone	DMI9PRJ	Rosacea	ED90.0	Approved	[70]
AllerB	DM78DOT	Allergy	4A80-4A85	Phase 2b	[71]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[72]
MANOALIDE	DMB4A8I	Arthritis	FA20	Phase 2	[73]
MRX-4	DMQZWYE	Allergic rhinitis	CA08.0	Phase 2	[74]
MRX-6	DMLVQKF	Contact dermatitis	EK0Z	Phase 2	[75]

Drug(s) Targeting Candida Mannose-6-phosphate isomerase (Candi PMI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfacetamide	DMZ6VEY	Acne vulgaris	ED80	Approved	[76]
Sulfoxone	DMAYX6P	Dermatitis herpetiformis	EB44	Approved	[76]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[1]
GNF-PF-5134	DM7850H	Discovery agent	N.A.	Investigative	[77]
GNF-PF-2272	DMONK0F	Discovery agent	N.A.	Investigative	[77]
NSC-66209	DMQ0S4B	Discovery agent	N.A.	Investigative	[77]

Drug(s) Targeting Staphylococcus D-amino acid aminotransferase (Stap-coc dat)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyridoxamine-5'-Phosphate	DMQ6POC	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Staphylococcus Beta-lactamase (Stap-coc blaZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tazobactam	DM3XNUI	Bacterial infection	1A00-1C4Z	Approved	[78]
Ceftolozane/tazobactam	DM9QWAH	Discovery agent	N.A.	Approved	[79]
Meropenem + vaborbactam	DMOVAIX	Intra-abdominal infection	1A40	Approved	[80]
Clavulanate	DM2FGRT	Bacterial infection	1A00-1C4Z	Approved	[81]
CAZ AVI	DMPG4OM	Serious infection	1H0Z	Phase 3	[82]
Enmetazobactam	DMZKTYJ	Urinary tract infection	GC08	Phase 3	[83]
Vaborbactam	DMDCFXJ	Urinary tract infection	GC08	Phase 3	[84]
MK-7655	DMLMV0O	Bacterial infection	1A00-1C4Z	Phase 2	[85]
CXL	DM3JFZ2	Methicillin-resistant staphylococci infection	1A00-1A09	Phase 2	[86]
RASV-Sp	DM4VTX6	Streptococcus infection	1B53	Phase 1	[87]

Drug(s) Targeting Calmodulin (CALM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halofantrine	DMOMK1V	Malaria	1F40-1F45	Approved	[88]
Trifluoperazine	DMKBYWI	Schizophrenia	6A20	Approved	[89]
Aprindine	DMBXWU8	Cardiac arrhythmias	BC9Z	Approved	[90]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[20]
Cacodylate Ion	DMK4XLD	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2-Propanol	DMHM5GJ	Discovery agent	N.A.	Investigative	[1]
N-Trimethyllysine	DMZQXLS	Discovery agent	N.A.	Investigative	[1]
Calmidazolium	DM5ZTJL	Huntington disease	8A01.10	Investigative	[91]

Drug(s) Targeting Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9200020, Table 3, Compound 1B	DMEARS2	N. A.	N. A.	Patented	[92]
US9200020, Table 3, Compound 2B	DMXFB5Z	N. A.	N. A.	Patented	[92]
US9200020, Table 3 compound 8	DMCLHX5	N. A.	N. A.	Patented	[92]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[1]
Pyrophosphate 2-	DMZQ75M	Discovery agent	N.A.	Investigative	[20]
Guanosine-5'-Monophosphate	DM3SLZK	Discovery agent	N.A.	Investigative	[1]
Inosinic Acid	DMLR86H	Discovery agent	N.A.	Investigative	[1]
Alpha-Phosphoribosylpyrophosphoric Acid	DMT6KI7	Discovery agent	N.A.	Investigative	[20]
Carboxylic PRPP	DMCTUR1	Discovery agent	N.A.	Investigative	[1]
5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine	DMX0EAK	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting GABA transaminase (ABAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-alanine	DMZDN4W	Dietary shortage	5B5K	Approved	[93]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[93]
Pyruvic acid	DM7Q41G	Malnutrition	5B50-5B71	Approved	[93]
Vigabatrin	DMYT0OG	Complex partial seizure	8A68.0	Approved	[94]
Divalproex sodium	DM4RK0G	Seizure disorder	8A6Z	Approved	[93]
CPP-115	DMK9NQI	Tourette syndrome	8A05.00	Phase 2	[95]
K-828-AB	DMJLNZQ	Dementia	6D80-6D86	Phase 2	[96]
CPP -15	DMQCHU3	Infantile spasm	8A62.0	Phase 1	[95]
T83193	DMHO29Y	Discovery agent	N.A.	Patented	[97]
4-hydroxybenzaldehyde	DM471P5	Discovery agent	N.A.	Patented	[98]

Drug(s) Targeting Dihydrodiol dehydrogenase type I (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[99]
ASP-9521	DM8V0UL	Prostate cancer	2C82.0	Phase 1/2	[100]
N-(benzimidazole/indole) benzoic acid derivative 2	DMOPUFM	N. A.	N. A.	Patented	[101]
N-(phenylamino)-benzoate derivative 1	DMNIWVG	N. A.	N. A.	Patented	[101]
Indomethacin analog 3	DM53JXE	N. A.	N. A.	Patented	[101]
Indomethacin analog 2	DMKFPJ7	N. A.	N. A.	Patented	[101]
Beta-naphthylacetic acids derivative 1	DM5KTDY	N. A.	N. A.	Patented	[101]
Indomethacin analog 1	DM3E5V6	N. A.	N. A.	Patented	[101]
N-(naphthylamino)-benzoate derivative 1	DM310ES	N. A.	N. A.	Patented	[101]
N-(benzimidazolylcarbonyl)-piperidine derivative 1	DM541QW	N. A.	N. A.	Patented	[101]

Drug(s) Targeting Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-157695	DMDSR1X	Schizophrenia	6A20	Preclinical	[102]
[3H]alphabeta-meATP	DMWV5C3	Discovery agent	N.A.	Investigative	[1]
[Pterin-6-Yl Methanyl]-Phosphonophosphate	DM4ZY79	Discovery agent	N.A.	Investigative	[1]
6-Hydroxymethyl-7,8-Dihydropterin	DMYF60K	Discovery agent	N.A.	Investigative	[1]
6-Hydroxymethylpterin	DM7EWDN	Discovery agent	N.A.	Investigative	[16]
P(1)-(6-Hydroxymethylpterin)-P(4)-(5'-adenosyl)tetraphosphate	DMOY627	Discovery agent	N.A.	Investigative	[102]

Drug(s) Targeting Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conjugated estrogens	DMLT0E1	Menopause symptom	GA30.0	Approved	[103]
Trilostane	DMQZ9GF	Cushing disease	5A70	Approved	[88]
ARZOXIFENE	DMOKCVI	Breast cancer	2C60-2C65	Approved	[104]
Estrogen	DMGY0UT	Menopause symptom	GA30.0	Approved	[105]
Premarin/Pravachol	DMLSOB7	Hyperlipidaemia	5C80	Phase 3	[106]
MF-101	DM8Z0I3	Hepatitis virus infection	1E50-1E51	Phase 3	[107]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[108]
AUS-131	DMZMSQJ	Hot flushes	GA30	Phase 2	[109]
ERB-041	DMCEPUA	Inflammatory bowel disease	DD72	Phase 2	[110]
Erteberel	DMU1XZD	Prostate hyperplasia	GA90	Phase 2	[111]

Drug(s) Targeting Angiotensin-converting enzyme (ACE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enalapril	DMNFUZR	Hypertension	BA00-BA04	Approved	[112]
Spirapril	DM5XLTY	Hypertension	BA00-BA04	Approved	[113]
Captopril	DM458UM	Hypertension	BA00-BA04	Approved	[114]
Benazepril	DMH1M9B	Hypertension	BA00-BA04	Approved	[115]
Moexipril	DM26E4B	Hypertension	BA00-BA04	Approved	[116]
Ramipril	DM2R68E	Congestive heart failure	BD10	Approved	[117]
Perindopril	DMOPZDT	Hypertension	BA00-BA04	Approved	[118]
Trandolapril	DM4L6EU	Hypertension	BA00-BA04	Approved	[119]
Fosinopril	DM9NJ52	Hypertension	BA00-BA04	Approved	[120]
Lisinopril	DMUOK4C	Hypertension	BA00-BA04	Approved	[121]

Drug(s) Targeting Thioredoxin (TXN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PX-12	DMLVHAJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[122]
Cacodylate Ion	DMK4XLD	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting PTPN1 messenger RNA (PTPN1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[123]
TRYPAN BLUE	DM4NTMO	Ophthalmic surgery injury	PK97	Approved	[124]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[125]
ISIS 113715	DMUPD4G	Type-2 diabetes	5A11	Phase 2	[126]
ISIS-PTP1Brx	DMJGVXT	Type-2 diabetes	5A11	Phase 2	[127]
ERTIPROTAFIB	DMJXEV7	Type-2 diabetes	5A11	Terminated	[128]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[1]
1,2-NAPHTHOQUINONE	DMYXELH	Discovery agent	N.A.	Investigative	[129]

Drug(s) Targeting Mycobacterium Thymidine monophosphate kinase (MycB tmk)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[20]
2'-deoxythymidine triphosphate	DM9OEJT	Discovery agent	N.A.	Investigative	[1]
Deoxythymidine	DMR90HY	Discovery agent	N.A.	Investigative	[1]
Diphosphate	DMHY30B	Discovery agent	N.A.	Investigative	[1]
Thymidine-5'-Phosphate	DMKM6NQ	Discovery agent	N.A.	Investigative	[1]
P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate	DMM4VWD	Discovery agent	N.A.	Investigative	[16]
3'-Azido-3'-Deoxythymidine-5'-Monophosphate	DMU08MN	Discovery agent	N.A.	Investigative	[1]
5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate	DMWVCJ1	Discovery agent	N.A.	Investigative	[1]
CHLORODEOXYURIDINE	DMQT3WJ	Discovery agent	N.A.	Investigative	[130]
BROMODEOXYURIDINE	DM0D7LA	Discovery agent	N.A.	Investigative	[130]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin-converting enzyme (ACE)	TTL69WB	ACE_HUMAN	Inhibitor	[1]
Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut)	TTY8KJS	DUT_ECOLI	Inhibitor	[1]
Bacterial Glucosamine-6-phosphate synthase (Bact glmS)	TTC67I0	GLMS_ECOLI	Inhibitor	[1]
Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK)	TT38ECI	HPPK_ECOLI	Inhibitor	[1]
Calmodulin (CALM)	TTV3NH6	CALM1_HUMAN; CALM2_HUMAN; CALM3_HUMAN	Inhibitor	[1]
Candida Mannose-6-phosphate isomerase (Candi PMI1)	TT915ZD	MPI_CANAL	Inhibitor	[1]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[1]
Dihydrodiol dehydrogenase type I (AKR1C3)	TT5ZWB6	AK1C3_HUMAN	Inhibitor	[1]
Estrogen receptor beta (ESR2)	TTOM3J0	ESR2_HUMAN	Inhibitor	[1]
GABA transaminase (ABAT)	TTT2LD9	GABT_HUMAN	Inhibitor	[1]
Hydroxyphenylpyruvate dioxygenase (HPD)	TT8DSFC	HPPD_HUMAN	Inhibitor	[1]
Leukotriene A-4 hydrolase (LTA4H)	TTXZEAJ	LKHA4_HUMAN	Inhibitor	[1]
Matrix metalloproteinase-12 (MMP-12)	TTXZ0KQ	MMP12_HUMAN	Inhibitor	[1]
Mycobacterium Biosynthetic alanine racemase (MycB alr)	TT6TMZU	ALR_MYCSM	Inhibitor	[1]
Mycobacterium Thymidine monophosphate kinase (MycB tmk)	TT5B8AX	KTHY_MYCTU	Inhibitor	[1]
Nitric-oxide synthase brain (NOS1)	TTZUFI5	NOS1_HUMAN	Inhibitor	[1]
Nitric-oxide synthase endothelial (NOS3)	TTCM4B3	NOS3_HUMAN	Inhibitor	[1]
Pancreatic elastase 1 (CELA1)	TT3NKIB	CELA1_HUMAN	Inhibitor	[1]
Phospholipase A2 (PLA2G1B)	TT9V5JH	PA21B_HUMAN	Inhibitor	[1]
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)	TT3PQ2Y	PYRD_PLAF7	Inhibitor	[1]
Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)	TTBL49X	HGXR_PLAFG	Inhibitor	[1]
PTPN1 messenger RNA (PTPN1 mRNA)	TTELIN2	PTN1_HUMAN	Inhibitor	[1]
Staphylococcus Beta-lactamase (Stap-coc blaZ)	TTHI19T	BLAC_STAAU	Inhibitor	[1]
Staphylococcus D-amino acid aminotransferase (Stap-coc dat)	TTN6GE9	DAAA_STAHA	Inhibitor	[1]
Superoxide dismutase Cu-Zn (SOD Cu-Zn)	TT6RVLG	SODC_HUMAN	Inhibitor	[1]
Thioredoxin (TXN)	TTZJ5U9	THIO_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [3] Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
• [4] Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
• [5] Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
• [6] Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
• [7] Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
• [8] Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.
• [9] Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
• [10] Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7.
• [11] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [12] Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
• [13] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [14] Clinical pipeline report, company report or official report of Vernalis.
• [15] Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
• [16] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
• [19] Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
• [20] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [21] Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
• [22] Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
• [23] Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83.
• [24] Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66.
• [25] Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61.
• [26] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [27] Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.
• [28] Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7.
• [29] Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8.
• [30] Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
• [31] Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36.
• [32] Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
• [33] SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5.
• [34] 4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target. Drug News Perspect. 2003 Oct;16(8):493-6.
• [35] Design, synthesis, and evaluation of postulated transient intermediate and substrate analogues as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2002 Jul 8;12(13):1709-13.
• [36] Molecular dynamics studies of alanine racemase: a structural model for drug design. Biopolymers. 2003 Oct;70(2):186-200.
• [37] Mechanism-based inactivation of alanine racemase by 3-halovinylglycines. J Biol Chem. 1991 Nov 15;266(32):21657-65.
• [38] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [39] ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
• [40] Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
• [41] Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
• [42] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [43] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [44] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [45] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [46] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [47] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [48] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [49] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [50] Elastase inhibitors. J Soc Biol. 2001;195(2):143-50.
• [51] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [52] Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
• [53] Biological activity of WIN 63759, an orally bioavailable inhibitor of human neutrophil elastase. Drug Development Research Volume 34, Issue 3, pages 306-316, March 1995.
• [54] Pivotal role for alpha1-antichymotrypsin in skin repair. J Biol Chem. 2011 Aug 19;286(33):28889-901.
• [55] EP patent application no. 1292314, Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans.
• [56] CN patent application no. 1813706, Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage.
• [57] Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
• [58] Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med. 1988 May;108(5):680-6.
• [59] Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
• [60] The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. Basic Clin Pharmacol Toxicol. 2005 Jul;97(1):29-34.
• [61] Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase: a novel biotechnology-based blood substitute that transports both oxygen and carbon dioxide and also acts as an antioxidant.Artif Cells Blood Substit Immobil Biotechnol.2011 Jun;39(3):127-36.
• [62] A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis
• [63] Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14.
• [64] Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59.
• [65] Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90.
• [66] Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J Med Chem. 2006 Jul 13;49(14):4183-95.
• [67] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [68] Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
• [69] Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
• [70] Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
• [71] Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
• [72] Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
• [73] Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
• [74] Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
• [75] A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.
• [76] Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54.
• [77] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [78] Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
• [79] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [80] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [81] A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
• [82] NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
• [83] Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
• [84] Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
• [85] Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
• [86] Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
• [87] WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
• [88] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [89] Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5.
• [90] Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6.
• [91] Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135.
• [92] 6-oxopurine phosphoribosyltransferase inhibitors. US9200020.
• [93] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [94] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [95] Clinical pipeline report, company report or official report of Catalyst Pharma.
• [96] Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
• [97] Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
• [98] Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
• [99] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [100] Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
• [101] Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
• [102] Bisubstrate analogue inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: synthesis and biochemical and crystallographic studies. J Med Chem. 2001 Apr 26;44(9):1364-71.
• [103] Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
• [104] Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
• [105] Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
• [106] Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
• [107] MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
• [108] Company report (Axcentua)
• [109] S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
• [110] Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
• [111] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
• [112] Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
• [113] Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
• [114] Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
• [115] Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
• [116] Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
• [117] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [118] Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
• [119] Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
• [120] Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
• [121] Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
• [122] 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther. 2008 Jan;7(1):143-51.
• [123] Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
• [124] Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6.
• [125] Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
• [126] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [127] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [128] 2-O-carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5357-60.
• [129] Synthesis and PTP1B inhibition of 1,2-naphthoquinone derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1941-6.
• [130] Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial ac... Bioorg Med Chem. 2008 Jun 1;16(11):6075-85.